強直性脊椎炎患者におけるイキセキズマブの長期安全性と有効性: COAST 試験の3年結果
J Rheumatol. 2023;50(8):1020–1028 doi: 10.3899/jrheum.221022
Three-year data from the ixekizumab (IXE) COAST programme provide additional evidence that patients with axSpA receiving IXE experience long-term safety, and sustained improvements in efficacy outcomes, at 3 years.